| 1. |
Verified serum or plasma PSA concentration >4.0 ng/mL |
| 2. |
An increase in serum or plasma PSA concentration >1 ng/mL after 3 or 6 mo
of testosterone treatment |
| 3. |
A PSA velocity of >0.4 ng/mL/y using the PSA level after 6 mo of
testosterone administration as the reference * |
| 4. |
Detection of a prostatic abnormality on digital rectal examination |
| 5. |
An AUA or IPSS prostate symptom score of >21 |
|
| *The recommendation for using PSA velocity threshold of 0.4 ng/mL/y
is not based on data, but it takes into consideration the findings of Fang et
al (2002) and those of Smith
and Catalona (1994). It
reflects our opinion based on considerations of interassay coefficient of
variation of PSA assays and these 2 reports. |
